ES2666397T3 - Activación de CD89 en terapia - Google Patents

Activación de CD89 en terapia Download PDF

Info

Publication number
ES2666397T3
ES2666397T3 ES11794757.2T ES11794757T ES2666397T3 ES 2666397 T3 ES2666397 T3 ES 2666397T3 ES 11794757 T ES11794757 T ES 11794757T ES 2666397 T3 ES2666397 T3 ES 2666397T3
Authority
ES
Spain
Prior art keywords
therapy
activation
molecule
activating molecule
activating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11794757.2T
Other languages
English (en)
Inventor
Stephan von Gunten
Marc Wehrli
Adrian ZÜRCHER
Sylvia Miescher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Bern
CSL Behring AG
Original Assignee
Universitaet Bern
CSL Behring AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Bern, CSL Behring AG filed Critical Universitaet Bern
Application granted granted Critical
Publication of ES2666397T3 publication Critical patent/ES2666397T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Una molécula activadora de CD89 para su uso en el tratamiento de una afección inflamatoria o un trastorno autoinmunitario, mediante la inducción de la apoptosis en neutrófilos, donde la molécula activadora de CD89 es una molécula que comprende Fc alfa, que se administra como una solución estéril.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES11794757.2T 2010-12-14 2011-12-14 Activación de CD89 en terapia Active ES2666397T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10194942 2010-12-14
EP10194942A EP2465536A1 (en) 2010-12-14 2010-12-14 CD89 activation in therapy
PCT/EP2011/072711 WO2012080306A1 (en) 2010-12-14 2011-12-14 Cd89 activation in therapy

Publications (1)

Publication Number Publication Date
ES2666397T3 true ES2666397T3 (es) 2018-05-04

Family

ID=43952841

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11794757.2T Active ES2666397T3 (es) 2010-12-14 2011-12-14 Activación de CD89 en terapia

Country Status (16)

Country Link
US (2) US9522184B2 (es)
EP (2) EP2465536A1 (es)
JP (1) JP6245986B2 (es)
KR (1) KR101946231B1 (es)
CN (1) CN103313728B (es)
AU (1) AU2011343392B2 (es)
BR (1) BR112013014669A2 (es)
CA (1) CA2821296A1 (es)
DK (1) DK2651440T3 (es)
ES (1) ES2666397T3 (es)
IL (1) IL226805B (es)
MX (1) MX355394B (es)
NZ (1) NZ610891A (es)
RU (1) RU2640082C2 (es)
SG (1) SG190917A1 (es)
WO (1) WO2012080306A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2465536A1 (en) * 2010-12-14 2012-06-20 CSL Behring AG CD89 activation in therapy
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
EP2636684A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
SG11201404958SA (en) 2012-03-09 2014-11-27 Csl Behring Ag Compositions comprising secretory - like immunoglobulins
US9458230B2 (en) 2013-01-04 2016-10-04 Wisconsin Alumni Research Foundation Secretory IGA compositions, methods of making and methods of use thereof
US9468674B2 (en) * 2013-09-24 2016-10-18 Wisconsin Alumni Research Foundation Methods of use of secretory IgA
US10668147B2 (en) 2015-03-25 2020-06-02 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Anti-CD89 cytotoxic complex
CN111278862A (zh) 2017-09-21 2020-06-12 Umc乌德勒支控股有限公司 用于治疗成神经细胞瘤的抗gd2抗体
KR20220004979A (ko) 2019-03-27 2022-01-12 유엠씨 우트레크트 홀딩 비.브이. 조작된 iga 항체 및 사용 방법
US20220133761A1 (en) * 2020-11-04 2022-05-05 Washington State University Neutrophil apoptosis induced by nanoparticles for treating inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ269735A (en) * 1993-07-30 1998-01-26 Oravax Inc Monoclonal iga antibody against respiratory syncytial virus (rsv)
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
WO1998057993A1 (en) * 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
CA2437814C (en) * 2001-02-12 2008-05-13 Medarex, Inc. Human monoclonal antibodies to fc alpha receptor (cd89)
US6932967B2 (en) * 2001-03-22 2005-08-23 Michael R. Simon Human medical treatment by aerosol inhalation of immunoglobulin A
US20060165675A1 (en) * 2002-08-02 2006-07-27 Richman-Eisenstat Janice Beth Modulation of mesenchymal cells via iga-receptors
AU2004282984B2 (en) * 2003-11-13 2011-07-14 Hanmi Science Co., Ltd. Protein complex using immunoglobulin fragment andmethod for the preparation thereof
EP2465536A1 (en) * 2010-12-14 2012-06-20 CSL Behring AG CD89 activation in therapy

Also Published As

Publication number Publication date
EP2651440B1 (en) 2018-01-24
US20170166640A1 (en) 2017-06-15
NZ610891A (en) 2015-05-29
MX355394B (es) 2018-04-18
RU2013132220A (ru) 2015-01-20
DK2651440T3 (en) 2018-05-07
MX2013006589A (es) 2014-02-06
EP2651440A1 (en) 2013-10-23
RU2640082C2 (ru) 2017-12-26
AU2011343392B2 (en) 2017-01-05
EP2465536A1 (en) 2012-06-20
SG190917A1 (en) 2013-07-31
KR20140048077A (ko) 2014-04-23
WO2012080306A1 (en) 2012-06-21
BR112013014669A2 (pt) 2016-11-29
CA2821296A1 (en) 2012-06-21
KR101946231B1 (ko) 2019-02-12
US20130302345A1 (en) 2013-11-14
CN103313728A (zh) 2013-09-18
IL226805B (en) 2019-10-31
JP6245986B2 (ja) 2017-12-13
CN103313728B (zh) 2016-11-09
US9522184B2 (en) 2016-12-20
JP2014502962A (ja) 2014-02-06
AU2011343392A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
ES2666397T3 (es) Activación de CD89 en terapia
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
GT201300215A (es) Inhibidores de glucosilceramida sintasa
NI201100075A (es) Agonistas del receptor gpr120 de arilo y usos de los mismos.
CR20150200A (es) Derivados de exendina-4 como agonistas duales de glp1/glucacón
CL2012001422A1 (es) Compuestos derivados de sulfonil benzamidas sustituidas, inductores de apoptosis con selectividad por bcl-2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
BR112012011086A2 (pt) uso de betanecol para o tratamento de xerostomia
CR20110622A (es) Conjunto de aguja para dispositivo para biopsias
CL2009000048A1 (es) Uso de compuestos derivados de triterpenoides en el tratamiento de insuficiencia renal, y enfermedades asociadas tales como: nefropatías, resistencia a la insulina, diabetes, patologías vasculares, entre otras.
CU24336B1 (es) Compuestos de imidazopirrolidinona
CO6400136A2 (es) Agosnistas del receptor gpr120 y usos de los mismos
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
BR112012002081B8 (pt) Dispositivo de tratamento bucal
AR065589A1 (es) Prediccion de respuesta a un inhibidor her
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
GT200900209A (es) Compuestos triciclos y su uso como moduladores del receptor de glucocorticosteroides
CR20140400A (es) Terapia combinada para el tratamiento del cancer de ovario
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
CL2016001578A1 (es) Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c.
ES2517491T3 (es) Estabilizador de los vasos linfáticos
ES2528366T3 (es) Citicolina para el tratamiento del glaucoma
NI201000173A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre.
AR095641A1 (es) Montaje de aireador para la difusión de un gas en un líquido